The frequency of vascular events and evolution to myelofibrosis (MF) in young individuals with essential thrombocythemia (ET) is not well known. The incidence and predisposing factors to such complications was studied in 126 subjects diagnosed with ET at a median age of 31 years (range: 5-40). Overall survival and probability of survival free of thrombosis, bleeding and MF were analyzed by the Kaplan-Meier method and the presence of the Janus Kinase 2 (JAK2) V617F mutation correlated with the appearance of such complications. The JAK2 mutation (present in 43% of patients) was associated with higher hemoglobin (Hb) (Po0.001) and lower platelets at diagnosis. With a median follow-up of 10 years (range: 4-25), 31 thrombotic events were registered (incidence rate: 2.2 thromboses/100 patients/year). When compared with the general population, young ET patients showed a significant increase in stroke (odds ratio 50, 95% CI: 21.5-115) and venous thromboses (odds ratio 5.3, 95% CI: 3.9-10.6). Thrombosis-free survival was 84% at 10 years, with tobacco use being associated with higher risk of thrombosis. Actuarial freedom from evolution to MF was 97% at 10 years. In conclusion, young ET patients have thrombotic events, especially stroke and venous thrombosis, more frequently than generally considered, whereas they rarely transform to MF.
Introduction
Essential thrombocythemia (ET) is a chronic myeloproliferative disorder associated with an increased tendency to thrombosis. 1, 2 Survival of ET patients has been reported to be similar to that of the general population during the 10 years post-diagnosis. 3 However, beyond the first decade, survival seems to be worse, 4 mainly owing to thrombosis and disease transformation. The frequency of evolution into myelofibrosis (MF) increases with disease duration, with the probability being 8% at 10 years, 5 whereas transformation to acute leukemia (AL) is uncommon and has been related to the administration of cytolytic therapy. 6 Median age at diagnosis of ET is in the sixth decade of life, with less than 20% of patients being diagnosed below 40 years. 7 In practice, the majority of the latter patients are considered at low risk of vascular complications and therefore managed in a conservative manner. However, information on the outcome of these patients is limited, since there are few reports on the subject, some of which include a small number of patients and have short follow-up. [8] [9] [10] [11] [12] Moreover, since the evolution to MF increases with disease duration and young ET patients have prolonged survival, the question arises as to whether transformation to MF could reduce their life expectancy.
Recently, a gain of function mutation exchanging valine to phenylalanine at position 617 (V617F) of the Janus Kinase 2 (JAK2) protein has been identified in most PV patients and half of those with ET. [13] [14] [15] [16] JAK2 V617F positive ET patients display some features similar to those of PV, such as higher Hb values and a higher frequency of venous thrombosis. 17 Although it has been reported that the V617F JAK2 mutation is less common in younger ET patients, 17, 18 the frequency of the mutation and the disease characteristics according to mutational status have not been studied in series including young ET patients only.
The objective of the present study was to assess the incidence of vascular complications, MF and AL in 126 subjects diagnosed with ET below the age of 40 years and to identify the factors associated with the development of such complications. The frequency of the JAK2 mutation and its relationship with the appearance of the above complications was also studied.
Patients and methods

Patient population and diagnostic criteria
Between 1981 and 2002, 126 subjects under the age of 40 years were consecutively diagnosed with ET at nine Spanish hospitals. As a rule, in all participant centers, informed consent for the scientific use of the patients' clinicohematological data and biological samples was obtained at diagnosis. The diagnosis of ET was based on the criteria of the Polycythemia Vera Study Group, 19 whereas the diagnoses of MF and AL were based on the criteria of the World Health Organization. 20 The silver stain for demonstration of bone marrow reticulin fibers was scored on a 0-2 scale, with grade 0 corresponding to absence of fibrosis, grade 1 to a minimally increased reticulin network and grade 2 to an increased reticulin network. The karyotype of bone marrow was analyzed whenever assessable metaphases could be obtained. The JAK2 V617F mutation was analyzed by an allele-specific PCR, using 100 ng of patient's DNA obtained from peripheral blood granulocytes or from archived bone marrow samples. 21 
Treatment
Given the retrospective nature of the study, treatment for ET varied over the years. As a general rule, cytotoxic treatment was avoided as much as possible unless major thrombotic or hemorrhagic complications were present. Eighty-one patients started on a wait-and-see approach exclusively but at the time of the analysis only 29 patients had not received any treatment modality. Sixty-nine patients received antiplatelet agents as monotherapy (usually acetylsalicylic acid, ASA, 100 mg daily) and 59 cytoreductive treatment, including hydroxyurea (n ¼ 35), anagrelide (n ¼ 36) and interferon alpha (n ¼ 13). Allogeneic stem cell transplantation was performed in two patients after evolution to MF and acute leukemia, respectively.
Vascular complications
For this study purpose, only major vascular events, defined according to the International Classification of Diseases (Ninth Revision), were considered. Arterial thromboses included: stroke, transient ischemic attacks (TIA), retinal artery occlusion, coronary arterial disease (angina pectoris or myocardial infarction) and peripheral arterial disease (intermittent claudication and thromboembolism of the leg arteries). Venous thromboses included cerebral venous sinus thrombosis, deep-vein thrombosis, pulmonary thromboembolism, Budd-Chiari syndrome and portal vein thrombosis. Minor occlusive events, such as erythromelalgia and superficial thrombophlebitis of the extremities, were not considered.
Major hemorrhage was defined as intracranial or retroperitoneal bleeding, overt hemorrhage associated with a Hb decrease X20 g/l or overt hemorrhage requiring transfusion.
Statistical methods
The vast majority of patients were followed at the original institution since diagnosis and their evolutive data were obtained from the medical records. Only three patients were lost for follow-up at 4.2, 6 and 7.6 years from diagnosis and they were censored at the time of last follow-up. In each patient, major thrombotic events occurring within the year preceding ET diagnosis, at disease presentation or after diagnosis (and, in these cases, the time lapse between diagnosis and the event) were recorded. To compare the rate of major thrombotic events in the series with the one in the general population, patients were distributed by age groups according to the distribution employed in the studies used for the comparison, which included peripheral arterial disease, 22 stroke, 23 venous thrombosis, 24 and coronary heart disease. 25 For each comparison, a ratio of the observed to the expected incidence of thrombotic events [22] [23] [24] [25] and a 95% confidence interval (CI) was calculated assuming a Poisson distribution. The following initial variables were analyzed at univariate level for their possible association with the occurrence of thrombosis, bleeding or MF: age, gender, previous history of thrombosis, presence of vascular risk factors (including arterial hypertension, current cigarette smoking, hypercholesterolemia and diabetes mellitus), platelet counts, Hb level, white blood cell counts, serum lactate dehydrogenase (LDH), presence and degree of marrow fibrosis, JAK2 mutational status and aspirin use. For such purpose, the Kaplan-Meier method was employed followed by the log-rank test. Significance was considered for P-values o0.05. The statistical analysis was performed using the SPSS 10.0 package (SPSS, Chicago, IL, USA).
Results
Patients' median age at ET presentation was 31 (5-40) years. Nine patients were younger than 15 years; 45 were men and 81 women. Distribution of the cardiovascular risk factors was: 40 patients were current smokers, nine had arterial hypertension, one diabetes mellitus and seven hypercholesterolemia. Thirtyeight patients had one cardiovascular risk factor, eight two factors and one three factors. Median platelet count was 850 (603-2400) Â 10 9 /l. Bone marrow biopsy at diagnosis was available in 120 patients, being hypercellular in 33. Reticulin fibrosis was scored as grade 0 in 56, grade 1 in 30 and grade 2 in 24 patients. None out of 102 patients with assessable metaphases showed chromosome abnormalities. The JAK2 mutation was detected in 44 of 103 assessable patients (43%). Patients' characteristics at ET diagnosis according to JAK2 mutational status and their main complications during the evolution are shown in Table 1 .
After a median follow-up of 10 (range: 4-25) years, three patients had died, resulting in a survival probability of 98% at 10 years. Causes of death included stroke, intracranial bleeding and complications of bone marrow transplantation performed after transformation to MF (one case each).
Thirty-one thrombotic events were registered in 25 patients (19.8 % of the series). With a follow-up of 1373 person/years, the incidence rate of thrombosis was 2.2 per 100 patients/year, being 3.3 per 100 patients/year in men and 1.7 per 100 patients/ year in women (difference not statistically significant). In nine patients, the thrombosis occurred within the year before diagnosis (three cases) or at disease presentation (six cases). Eighteen patients (two of whom with a previous history of thrombosis) developed one or more thrombotic episodes during evolution (14.3% of the patients). Table 2 summarizes the type and number of thrombotic events. As can be seen, the thromboses were arterial and venous and the cerebrovascular tree was the territory most frequently involved. In one patient the thrombosis (stroke) represented the cause of death. Of the four subgroups of thrombosis considered (i.e., venous thrombosis, stroke, peripheral arterial disease and coronary heart disease), venous thromboses and stroke were the most frequent ones, with an incidence rate of 0.8 TIAs per 100 patients/year, 0.58 venous thromboses per 100 patients/year, 0.4 strokes per 100 patients/year and 0.2 events per 100 patients/year for coronary and peripheral artery disease, respectively. When compared with the general population, ET patients showed a significant increase in the incidence of stroke (odds ratio 50, 95% CI: 21.5-115). Venous thromboses were also significantly increased (odds ratio 5.3, 95% CI: 3.9-10.6), whereas no significant increase in coronary and peripheral arterial disease was noted. Considering only the thrombotic events that occurred after ET diagnosis, probability of thrombosis-free survival at 5 and 10 years was 92 and 84%, respectively (Figure 1a ). Survival free of arterial thrombosis was 93 and 89% at 5 and 10 years, respectively, whereas the corresponding figures for survival without venous thrombosis were 98 and 95%. Table 3 shows the main clinicohematological data at the time of the first thrombotic complication post-diagnosis. As can be seen, seven patients had received antiplatelet agents and three hydroxyurea (one of them in combination with aspirin), whereas the remaining nine had never been treated before the thrombosis. At univariate analysis, tobacco use was the only factor associated with an increased risk for appearance of thrombosis, being the probability of thrombosis-free survival 72% at 10 years for smokers versus 90% for non-smokers (P ¼ 0.02, Figure 1b) . Age, gender, prior thrombosis, hypercholesterolemia, JAK2 mutational status, platelet count and Hb value at diagnosis were not associated with increased risk of thrombosis.
Major bleeding was observed in 11 patients (8.7%), representing the cause of death in one case (a spontaneous intracranial hemorrhage). In the remaining cases the site of bleeding was the gynecological tract (six cases), the peritoneum (two cases), the urological tract (one case after renal trauma) and the upper digestive tract (gastric ulcer, one case). Median time from ET diagnosis to hemorrhagic complication was 4 (range 0.1-10) years. At time of bleeding, two patients were receiving aspirin alone and one hydroxyurea plus aspirin, while the remaining eight had never been treated. Median platelet count at time of hemorrhagic complication was 1279 (range 424-1922) Â 10 9 /l. Probability of bleeding-free survival at 5 and 10 years was 94 and 92%, respectively. Age, gender, initial Hb and platelet count, aspirin treatment and JAK2 mutational status were not associated with an increased bleeding risk.
Transformation to MF was observed in six cases (4.7%) at a median of 9 years from diagnosis, corresponding to four men and two women with a median age at MF diagnosis of 41 (range: 25-53) years. In these six cases, review of the marrow biopsies performed at ET diagnosis allowed to rule out the 'prefibrotic' form of MF. 20 The JAK2 mutation was present in one out of five assessable patients (P not significant). Figure 2a depicts the probability of MF-free survival in the series, being 99% at 5 years, 97% at 10 years and 89% at 15 years. Among the six patients developing MF, one had received cytolytic therapy for ET (hydroxyurea for 11 years, followed by anagrelide for 4 years) and the remaining five had never been treated. The variables associated with higher risk of myelofibrotic transformation were increased reticulin network in the initial marrow biopsy (Figure 2b) , increased LDH at diagnosis (Figure 2c) , and male gender. Probability of MF-free survival at 10 years was 90% for patients with grade 2 reticulin fibrosis versus 99% for patients with grade 0-1 fibrosis (P ¼ 0.005), 87% for patients with increased serum LDH versus 100% for those with normal LDH (P ¼ 0.04), and 95% for males versus 98% for females (P ¼ 0.04). One patient received an allogeneic bone marrow transplantation and died due to transplant-related complications. Other patient, diagnosed with ET 9 years earlier, subsequently found to be JAK2 negative, had never received cytolytic therapy and developed acute leukemia at 2 years of MF transformation.
Diffuse large B-cell lymphoma was diagnosed in one patient at 5 years of diagnosis of JAK2-negative ET. No other hematologic malignancies or solid tumors were registered. Years after diagnosis 
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Discussion
The present study was aimed at evaluating JAK2 mutational status, vascular complications and disease transformation in young patients with ET. It represents the largest study on the subject and the one with the longest follow-up, as well as the first including data on JAK2 mutational status.
The frequency of the JAK2 V617F mutation was similar to that reported in general ET series. [13] [14] [15] [16] [17] As reported previously by Campbell et al. 17 in a general ET series including 806 patients, young ET patients carrying the JAK2 mutation displayed higher Hb and leukocyte values and lower platelet counts, suggesting that JAK2-positive patients would constitute a homogeneous clinical entity. On the contrary, we could not confirm the increased frequency of venous thrombosis recently reported by the above authors in JAK2-positive ET. 17 Thrombosis was the most frequent complication in the present series, with a cumulative incidence rate of 2.2 thromboses/100 patients/year. These results are in keeping with the cumulative incidence rate of 2.6 thromboses/100 patients/year reported by Randi et al. 12 in 68 young ET patients followed for a median of 8 years, in which no comparison was established with data from the general population. On the other hand, the figure obtained for the women of the present study was close to the 1.2 thromboses/100 patients/year registered by Tefferi et al. 8 in 74 young women with ET followed for a median of 9 years. When compared with data from the general population, a significant increase in stroke and venous thromboses was noted, in agreement with previous observations suggesting a higher incidence of cerebral and venous thromboses in young individuals with ET. 12, 26 When only the thrombotic events developing after ET diagnosis were considered, the actuarial probability of thrombosis was 16% at 10 years. This figure is lower than the ones reported in general ET series, including a high proportion of older patients. 2, 27 In this sense, in a previous study from our group the actuarial probability of major thromboses was 27% at 6 years, 2 whereas in the prospective study by Cortelazzo et al.
27
including only patients at high risk of thrombosis, the probability was 30% at 3 years for untreated patients versus 5% for patients receiving hydroxyurea. 27 Moreover, the five-year risk of arterial and venous thrombosis observed in our young patients was similar to that registered in the largest prospective ET study, 28 which included patients at high risk of thrombosis receiving cytoreductive treatment. When the factors associated with a higher risk of thrombosis were studied, smoking was the only predictive factor, with the actuarial probability of thrombosis being 72% at 10 years in smokers. The latter figure is similar to the rates reported in older ET patients. 2, 27 No specific information on the possible influence on thrombosis occurrence of the patients' tobacco use was provided in the previously published series of young ET patients. 8, 12 However, in the study by Randi et al. 12 cardiovascular risk factors as a whole were significantly more frequent in patients developing major arterial thromboses. This observation would reinforce the importance of an adequate control of the cardiovascular risk factors in young individuals with ET.
Major bleeding occurred in 8.7% of our patients, for a bleeding-free survival probability of 92% at 10 years, a figure similar to that reported in general ET series. 5, 27, 28 Although no risk factor for such complication could be identified, it is of note that in most patients with bleeding platelet counts were over 1000 Â 10 9 /l at the time of complication, which should be taken into account when deciding which patients are candidates to cytoreductive treatment.
Transformation to MF was lower in our young ET patients than in the 195 unselected ET patients analyzed in a previous study from our group. 5 It must be remarked that none of the patients subsequently developing such complication fulfilled the criteria of the so-called 'prefibrotic' form of MF at ET presentation. 20 Of note, five of the six patients evolving into MF had never received treatment, suggesting that this complication would be part of the natural history of the disease. Male gender, increased serum LDH and, especially, reticulin fibrosis at the initial marrow biopsy could help to identify the subgroup of patients at higher MF risk. On the other hand, and in keeping with previous Table 3 Main clinicohematological data at time of first thrombotic event after diagnosis of ET in 126 young patients 10 transformation to acute leukemia was exceedingly infrequent.
In conclusion, young individuals with ET have vascular complications more frequently than generally considered, with this especially applying to stroke and venous thrombosis. The frequency of the JAK2 mutation and the disease characteristics according to mutational status do not seem to differ from those in older patients. Finally, disease transformation is rare in these patients.
Years after diagnosis Figure 2 (a) Overall probability of MF-free survival in 126 young patients with essential thrombocythemia; (b) probability of MF-free survival according to the presence or not of reticulin fibrosis in the initial marrow biopsy; (c) probability of MF-free survival according to initial serum LDH levels.
